My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$MRO {{ '2015-10-29T23:48:59+0000' | timeago}} • Announcement

$MRO cuts its quarterly dividend by 76%. Its BoD declared a quarterly dividend of $0.05 per share compared to the previous quarterly dividend of $0.21 per share. The dividend is payable on Dec. 10, 2015, to stockholders of record on Nov. 18, 2015. The adjustment to the dividend is expected to increase annual free cash flow by more than $425MM.

User Vishnu Beri {{ '2016-10-25T21:15:45+0000' | timeago}}

Apple ($AAPL) reported decline in sales and profits from comparable quarter last year, attributing the decline to announcement of iPhone 7/7s. Sales and profit are being guided higher for next quarter. Apple is a solid company and will continue to dominate tech and consumer electronics segment for a while. Personally, looks like there is little downside in this investment.

User Mark Collas {{ '2016-10-25T20:12:01+0000' | timeago}}

Waiting with fingers crossed for $AAPL’s fourth quarter earnings.

User RC xNair {{ '2016-10-25T17:04:47+0000' | timeago}}

Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."

User Carlton Davis {{ '2016-10-24T19:31:20+0000' | timeago}}

$COL agreed to buy $BEAV for $6.4 billion in cash and stock. Also Rockwell Collins reported higher 4Q16 earnings on growth in Government Systems and higher revenue in Information Management Services.

User Charles Elliston {{ '2016-10-24T19:15:21+0000' | timeago}}

Wow! What a buzz the $T-$TWX deal is making! Almost everyone from politicians to competitors have come out against this deal. Even Wall Street doesn’t seem to be too thrilled. Both stocks were down today.

$KO {{ '2016-10-26T13:21:34+0000' | timeago}} • Webcast

$KO's core business performed well with a 4% organic revenue growth YTD, in line with the company's long term target. Additionally, within the core business, developed markets performed well, with a YTD unit case volume growth of 2%.

$MDLZ {{ '2016-10-26T13:21:06+0000' | timeago}} • Announcement

Food and confectionery giant $MDLZ reported a 3Q16 profit of $0.35, down 92% due to prior year's $7Bil gain related to the company's coffee business transactions. Net revenues decreased 6.6% to $6.4Bil.

$BIIB {{ '2016-10-26T13:15:56+0000' | timeago}} • Webcast

$BIIB's Tysabri worldwide revenue was $515MM in 3Q16, an increase of 7% versus last year. This included $301MM in the US and $214MM outside the US. Tysabri revenue outside the US benefited by $20MM, due to a favorable adjustment to the company's discounts in allowances. ForEx and the hedge impact weakened Tysabri sales by approx. $16MM versus 3Q15.

$CMCSA {{ '2016-10-26T13:13:33+0000' | timeago}} • Webcast

$CMCSA's consolidated Capex increased 11.1% to $2.4Bil in 3Q16. During 3Q16, the company paid dividends totaling $663MM and repurchased 20.8MM of its common shares for $1.4Bil.

$BIIB {{ '2016-10-26T13:13:06+0000' | timeago}} • Webcast

$BIIB stated that Interferon revenues, including both Avonex and Plegridy, were $708MM during 3Q16, a decrease of 10% versus last year. This included $506MM in the US and $203MM in sales outside the US. In the US, there was a drawdown of Avonex inventory in the wholesale channel, resulting approx. $10MM versus 2Q16.